araag2/HINT huggingface dataset:
Clinical trial NCT02246621 (phase 3, status: active, not recruiting)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: abemaciclib, anastrozole, letrozole, placebo
SMILES: CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a diagnosis of hormone receptor-positive (HR+), human epidermal growth factor
             receptor 2-negative (HER2-) breast cancer

          -  Have locoregionally recurrent disease not amenable to resection or radiation therapy
             with curative intent or metastatic disease

          -  Have postmenopausal status

          -  Have either measurable disease or nonmeasurable bone-only disease

          -  Have a performance status ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale

          -  Have adequate organ function

          -  Have discontinued previous localized radiotherapy for palliative purposes or for lytic
             lesions at risk of fracture prior to randomization and recovered from the acute
             effects of therapy

          -  Are able to swallow capsules

        Exclusion Criteria:

          -  Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis

          -  Have inflammatory breast cancer

          -  Have clinical evidence or a history of central nervous system (CNS) metastasis

          -  Are currently receiving or have previously received endocrine therapy for
             locoregionally recurrent or metastatic breast cancer

          -  Have received prior (neo)adjuvant endocrine therapy with a disease-free interval ≤12
             months from completion of treatment

          -  Are currently receiving or have previously received chemotherapy for locoregionally
             recurrent or metastatic breast cancer

          -  Have received prior treatment with everolimus

          -  Have received prior treatment with any cyclin-dependent kinase (CDK) 4/6 inhibitor (or
             participated in any CDK4/6 inhibitor clinical trial for which treatment assignment is
             still blinded)

          -  Have initiated bisphosphonates or approved receptor activator of nuclear factor
             kappa-B ligand (RANK-L) targeted agents <7 days prior to randomization

          -  Are currently receiving an investigational drug in a clinical trial or participating
             in any other type of medical research judged not to be scientifically or medically
             compatible with this study

          -  Have received treatment with a drug that has not received regulatory approval for any
             indication within 14 or 21 days of randomization for a nonmyelosuppressive or
             myelosuppressive agent, respectively

          -  Have had major surgery within 14 days prior to randomization
Clinical trial NCT02247401 (phase 3, status: completed)
Conditions: hcv, hepatitis c infection, genotype 4
ICD codes: B17.0
Drugs: 2 daa, rbv
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic hepatitis C, genotype 4-infection (hepatitis C virus [HCV] ribonucleic acid
             [RNA] level greater than 1,000 IU/mL at Screening)

          -  Subjects must meet one of the following:

               -  Treatment-naive: Subject has never received antiviral treatment for HCV infection
                  OR

               -  Treatment Experienced (Prior null responders, Partial responders or Relapsers to
                  pegylated-interferon [pegIFN]/RBV);

          -  Females must be post-menopausal, of non-child bearing potential or practicing specific
             forms of birth control

          -  In substudy 1, demonstrated absence of liver cirrhosis as confirmed by liver biopsy or
             Fibroscan

          -  In substudy 2, evidence of liver cirrhosis as confirmed by liver biopsy or Fibroscan
             with Child-Pugh score less than or equal to 6 at Screening and confirmed absence of
             hepatocellular carcinoma

        Exclusion Criteria:

          -  Females who are pregnant or breastfeeding

          -  Positive screen for hepatitis B Surface antigen or anti-Human Immunodeficiency virus
             antibody

          -  HCV genotype performed during screening indicating unable to genotype or co-infection
             with any other HCV genotype

          -  abnormal laboratory tests

          -  self-reports current drinking more than 2 drinks per day

          -  current enrollment in another investigational study

          -  previous treatment with a direct acting antiviral agent (DAA) containing regimen

          -  In substudy 1, evidence of liver cirrhosis

          -  In substudy 2, evidence of current or past Child-Pugh B or C classification and
             confirmed presence of hepatocellular carcinoma
Clinical trial NCT02247687 (phase 3, status: terminated)
Conditions: hiv-1 infection, treatment resistant disorders, viremia
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: protease inhibitor, isentress® (raltegravir)
SMILES: CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1
Reason stopped: 
    low recruitment of participants for the study
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥ 18 years

          -  HIV-1 infection

          -  On combined antiretroviral regimen for at least 18 months

          -  Participant with a stable antiretroviral regimen for at least 6 months, including 2
             Reverse-transcriptase inhibitor (INTI) + 1 Boosted Protease Inhibitor IP/r ,

          -  participant with at least 2 consecutive viral load between 50 and 500
             copies/milliliter over the last 9 months (with at least 2 months between the two
             measurements) quantified with the same commercial kit.

          -  50 <or= VL < 500 copies/milliliter at screening visit quantified with the same
             commercial kit than previous one.

          -  Participant naïve to raltegravir (RAL)

          -  failure of amplification or successful realization of genotypic resistance test
             without evidence for resistance mutations against current treatment (3TC/FTC accepted
             with M184V mutation)

          -  creatinin < 3 Upper Limit normal (ULN)

          -  Aspartate Amino Transférase (ASAT), Alanine Amino Transférase (ALAT) < 5 Upper Limit
             normal (ULN)

          -  hemoglobin > 8 g/dL

          -  platelets > 50 000/mm3

          -  In women, lack of current pregnancy verified by Beta Human Chorionic Gonadotropin
             (βHCG) at week -4 visit and use of a mechanical contraceptive method

          -  Informed consent

          -  Participants with an active health insurance coverage (article L1121-11 du Code de la
             Santé Publique)

        Exclusion Criteria:

          -  HIV-2 infection,

          -  severe medical condition in the last month (inclusion is possible for a stable
             condition at screening)

          -  breastfeeding women, current pregnancy or planned pregnancy within 12 months.

          -  participant currently receiving Prezista® (darunavir)/ Norvir® (ritonavir) (600/100
             mg) two times a day (BID) (of note, participants receiving Prezista® (darunavir)/
             Norvir® (ritonavir) one time a day (QD) can be included)

          -  Hypersensitivity Prezista® (darunavir)/ Norvir® (ritonavir) or to any of the
             excipients of the study treatment

          -  participant under judicial protection (judicial protection due to temporarily and
             slightly diminished mental or physical faculties), or under legal guardianship

          -  planned absence that could prevent the patient from participating in the trial (travel
             abroad, moving, pending work transfer ...)
Clinical trial NCT02247804 (phase 3, status: completed)
Conditions: glaucoma, open-angle, ocular hypertension
ICD codes: H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131, H40.053, H40.051, H40.052, H40.059
Drugs: bimatoprost sr, active comparator: timolol 0.5%, timolol vehicle (placebo)
SMILES: CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1, [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1, [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1
Eligibility criteria:

        Inclusion Criteria:

        -Diagnosis of either open-angle glaucoma or ocular hypertension in each eye and both eyes
        require IOP-lowering treatment.

        Exclusion Criteria:

          -  Previous enrollment in another Allergan Bimatoprost SR Study.

          -  Eye surgery (including cataract surgery) and/or any eye laser surgery within the past
             6 months in the study eye

          -  Anticipated need for laser eye surgery in either eye within the first 52 weeks of the
             study duration

          -  History of glaucoma surgery
Clinical trial NCT02250391 (phase 3, status: completed)
Conditions: portal vein thrombosis
ICD codes: I81
Drugs: npb-06, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Inpatients or outpatients meet the criteria (1)-(4) below will be enrolled in the study.
        Patients have to provide written informed consent for voluntary participation in the study.

          1. Patients who the serum level of AT-III is 70% or less

          2. Patients with portal vein thrombosis detected by ultrasonography

          3. Patients who have more than 50% of the thrombus lumen occupancy

          4. Patients who are older than 20 years at the time of consent

        Exclusion Criteria:

        Patients who meet any of the following criteria will be excluded from the study beforehand.

          1. Patients with tumor embolus in portal vein

          2. Patients with an ongoing hepatic intra-arterial chemotherapy such as implantable
             reservoir system

          3. Patients with hepatocellular cancer of more than 3 cm in diameter or more than four
             hepatocellular cancers

          4. Patients with residual or chronic portal vein thrombosis

          5. Patients with advanced liver disease (Child-Pugh score 11 or more)

          6. Patients with bleeding tendency

          7. Patients who had an anticoagulation therapy (intravenous or subcutaneous dose) or
             hemostasis with an enzymatic hemostatic agent in the period between 7 days before
             contrast enhanced CT of pre-dose and the day acquired written informed consent

          8. Patients who had an anticoagulation therapy (oral dose) in the period between 7 days
             before contrast enhanced CT of pre-dose and the day acquired written informed consent

          9. Patients with a history of shock or hypersensitivity to NPB-06

         10. Patients with inappropriate to contrast agents

               -  A history of allergy of iodine or X-ray contrast agent

               -  Complication of serious thyroid disease

               -  Reduced renal function

         11. Pregnant or lactating women, women of childbearing potential, or women who plan to
             become pregnant during the study

         12. Patients who have received NPB-06

         13. Patients who have received other investigational drugs within four months before
             consent or who are participating in other clinical studies

         14. Patients otherwise ineligible for participation in the study in the investigator's or
             subinvestigator's opinion
Clinical trial NCT02250651 (phase 3, status: completed)
Conditions: glaucoma, open-angle, ocular hypertension
ICD codes: H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131, H40.053, H40.051, H40.052, H40.059
Drugs: bimatoprost sustained-release, timolol, timolol vehicle (placebo)
SMILES: CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1, [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1, [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1
Eligibility criteria:

        Inclusion Criteria:

        - Diagnosis of either open-angle glaucoma or ocular hypertension in each eye and both eyes
        require IOP-lowering treatment.

        Exclusion Criteria:

          -  Previous enrollment in another Allergan Bimatoprost SR Study

          -  Eye surgery (including cataract surgery) and/or any eye laser surgery within the past
             6 months in the study eye

          -  Anticipated need for laser eye surgery within the first 52 weeks of the study duration

          -  History of glaucoma surgery
Clinical trial NCT02250807 (phase 3, status: completed)
Conditions: chronic hepatitis c, genotype 4 chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: simeprevir, sofosbuvir
SMILES: [H]\C1=C([H])\[C@]2([H])C[C@]2(N=C(O)[C@]2([H])C[C@]([H])(C[C@@]2([H])C(=O)N(C)CCCC1)OC1=C2C=CC(OC)=C(C)C2=NC(=C1)C1=NC(=CS1)C(C)C)C(O)=NS(=O)(=O)C1CC1, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with confirmed hepatitis C virus (HCV) with HCV RNA greater than (>) 10000
             international unit per milliliter (IU/mL)

          -  Subjects who are treatment naive or treatment-experienced.

          -  Subjects must have documentation of a liver biopsy or fibroscan or agree to have one
             during screening

          -  Subjects with cirrhosis must have an hepatic imaging procedure (ultrasound, CT scan or
             magnetic resonance imaging [MRI]) within 6 months before the screening visit (or
             during the screening period) with no findings suspicious for hepatocellular carcinoma
             (HCC)

          -  Women of childbearing potential or men with a female partner of childbearing potential
             must agree to use an effective form of contraception, or not be heterosexually active,
             or of nonchildbearing potential

        Exclusion Criteria:

          -  Evidence of clinical hepatic decompensation

          -  Any liver disease of non-HCV etiology

          -  Subjects with a past history of treatment with an approved or investigational DAA

          -  Co-infection with human immunodeficiency virus (HIV) type 1 or type 2 (HIV-1 or HIV-2)
             (positive HIV-1 or HIV-2 antibodies test at screening)

          -  Infection/co-infection with HCV non-genotype 4
Clinical trial NCT02251977 (phase 3, status: completed)
Conditions: colorectal cancer, chemotherapy-induced neutropenia
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, D61.810
Drugs: gm1, placebo, mfolfox6 or xelox
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, FC1=CNC(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age: 18-75 years old, male or female

          -  Histologically confirmed diagnosis of colorectal adenocarcinoma with a phase II or III
             disease, within 2 months from radical resection, and intends to receive 6 months of
             adjuvant chemotherapy with mFOLOFX6 or XELOX, without adjuvant radiation indications

          -  No prior any level of peripheral nerve system disease

          -  Patients have not received any other possible neurotoxic-reaction-causing drugs (such
             as oxaliplatin, cisplatin and paclitaxel drugs etc)

          -  With the capability to accurately record the occurrence and severity of neurotoxicity
             by questionnaire

          -  With normal functions of major organs

          -  No contraindication to chemotherapy

          -  Life expectancy ≥ 3 months

          -  Patients have provided a signed Informed Consent Form

        Exclusion Criteria:

          -  Patients who received radical resection, but are expected not be able to complete 6
             months of adjuvant chemotherapy

          -  Patients who receive palliative chemotherapy

          -  Patients who need adjuvant or palliative radiotherapy during chemotherapy

          -  Be allergic to GM1

          -  Hereditary abnormal metabolism of glucose and lipid

          -  Doctors believe that patients are not suitable for receiving GM1 treatment

          -  With confirmed history of neurological or psychiatric disorders, including epilepsy
             and dementia

          -  With concomitant diseases that will seriously harm the patients' safety or impact the
             completion of the study

          -  Patients (male or female) have fertility possibility but not willing or not to take
             effective contraceptive measures
Clinical trial NCT02251990 (phase 3, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: grazoprevir/elbasvir, placebo
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(=CN1)C1=CC2=C(C=C1)N1[C@@H](OC3=C(C=CC(=C3)C3=CNC(=N3)[C@@H]3CCCN3C(=O)[C@@H](NC(=O)OC)C(C)C)C1=C2)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Has documented chronic HCV GT1, GT4, or GT6 (with no evidence of non-typeable or mixed
             genotype) infection

          -  Meets clinical criteria for presence or absence of cirrhosis based on liver disease
             staging assessment

          -  Is abstinent or uses acceptable method(s) of contraception

        Exclusion Criteria:

          -  Has evidence of decompensated liver disease

          -  Is coinfected with hepatitis B virus or human immunodeficiency virus (HIV)

          -  Shows evidence of hepatocellular carcinoma (HCC) or is under evaluation for HCC

          -  Has a clinically-relevant drug or alcohol abuse within 12 months of screening

          -  Is pregnant or breast-feeding

          -  Has any condition or abnormality that might confound the results of the trial or pose
             an additional risk to the participant
Clinical trial NCT02252016 (phase 3, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: grazoprevir + elbasvir, placebo
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(=CN1)C1=CC2=C(C=C1)N1[C@@H](OC3=C(C=CC(=C3)C3=CNC(=N3)[C@@H]3CCCN3C(=O)[C@@H](NC(=O)OC)C(C)C)C1=C2)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  has HCV GT1, GT4, or GT6 with sickle cell anemia, thalassemia, or hemophilia/von
             Willebrand disease

          -  has cirrhosis or is non-cirrhotic

          -  is human immunodeficiency virus (HIV) coinfected or not infected with HIV

          -  is a female of non childbearing potential, or is male or female and uses an acceptable
             method(s) of contraception

        Exclusion Criteria:

          -  has evidence of decompensated liver disease

          -  is coinfected with hepatitis B

          -  has had a malignancy ≤5 years prior to signing informed consent except for adequately
             treated basal cell or squamous cell skin cancer or in situ cervical cancer

          -  has hepatocellular carcinoma (HCC) or is under evaluation for HCC

          -  has clinically-relevant drug or alcohol abuse within 12 months of screening
Clinical trial NCT02253459 (phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: utd1 injection plus capecitabine, capecitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          1. Histologically and/or cytologically diagnosed patients with advanced, metastatic
             breast cancer,or lacking standard therapy or being failed to or recurrent after
             standard therapy;

          2. Patients who have previously treated with ≤4 chemotherapeutic regimes;

          3. Patients who have previously treated with an anthracyclin antibiotics and a taxane;

          4. Age 18 -70 years old, ECOG performance status of 0-2; Life expectancy of 3 months or
             more;

          5. Patients with at least 1 measurable target lesion determined by CT within 2 weeks
             prior to enrollment;

          6. Neuropathy <CTC2 degree （NCI CTC4.03）within 4 weeks prior to enrollment;

          7. Basically normal results from routine blood test within 1 week prior to enrollment;

          8. Basically normal liver and renal functions within 1 week prior to enrollment;

          9. No abnormal function for major internal organs, no heart diseases.

        Exclusion Criteria:

          1. Received chemotherapy, radiotherapy, therapies with hormones or molecularly targeted
             drugs 4 weeks prior to enrollment, or received other chemotherapies while
             participating in this trial;

          2. Patients with documented hypersensitivity to Cremophor EL, or patients with previous
             taxane treatment related SAE;

          3. Patients of pregnancy or breast feeding;

          4. Patients with previous standard capecitabine treatment ineffective, or patients
             received standard capecitabine treatment effective, but with less than 6 months of
             capecitabine clearance period;

          5. Patients with uncontrolled brain metastasis or bone metastasis, which plan for recent
             surgery or local radiotherapy, or other emergency treatment;

          6. Patients combined with severe and /or uncontrolled medical conditions, including
             severe cardiovascular disease, uncontrolled diabetes and high blood pressure, severe
             infection, severe gastrointestinal ulceration, and patients with incontrollable
             psychiatric history;

          7. Patients with poor compliance;

          8. Patients not fitted for this study determined by the investigators.
Clinical trial NCT02255370 (phase 3, status: completed)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: curcumin
SMILES: COC1=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC(OC)=C(O)C=C2)=CC=C1O
Eligibility criteria:

        Inclusion Criteria:

          -  Crohn's disease confirmed by radiographic, endoscopic or histologic criteria

          -  Age > 18 yr

          -  Affiliated to french health insurance

          -  Operated on less than 15 days ago for ileal, colonic or ileo-colonic Crohn's disease
             with all macroscopic lesions being removed, with an anastomosis which can be reached
             by ileocolonoscopy

        Exclusion Criteria:

          -  Ulcerative colitis

          -  Pregnant or nursing woman

          -  Refusal of contraceptive measure for childbearing potential, woman or fertile man

          -  Indication of anti-TNFα treatment

          -  Concomitant treatment including antibiotics, probiotics, mesalazine, methotrexate,
             cyclosporine, tacrolimus, anti-TNFα, ustekinumab, vedolizumab

          -  Concomitant treatment with corticosteroids, except in case of tapering a treatment
             initiated before surgery

          -  Renal insufficiency ( serum creatinine 2N)

          -  Chronic hepatic disease except for primary sclerosing cholangitis

          -  ALAT , ASAT, alkaline phosphatases, or bilirubin > 3N

          -  Current infection to HIV, HBV (except if HBV Ac positives), HCV

          -  Contraindication to thiopurines

          -  Unwillingness of the patient